Diagnosis and management of polymyalgia rheumatica/giant cell arteritis

Carlo Salvarani, Luigi Macchioni, Ignazio Olivieri, Fabrizio Cantini, Luigi Boiardi

Research output: Contribution to journalArticle

Abstract

There are no standardised diagnostic criteria for polymyalgia rheumatica. The combination of persistent pain (at least 1 month) with marked morning stiffness in at least 2 of the neck, shoulder or pelvic girdle is characteristic of polymyalgia rheumatica. The other criteria are age >50 years, erythrocyte sedimentation rate (ESR) >40 mm/hour, rapid response to corticosteroids and an absence of other diseases capable of causing the musculoskeletal symptoms. A normal ESR does not exclude a diagnosis of polymyalgia rheumatica. Diagnostic temporal artery biopsy is recommended in all patients suspected of having giant cell arteritis. The segment of temporal artery with abnormality on physical examination should be biopsied. The drugs of choice in the treatment of polymyalgia rheumatica/giant cell arteritis are corticosteroids. An initial prednisone dosage of 40 to 60 mg/day is adequate in almost all cases of giant cell arteritis. Higher dosages and/or intravenous pulse methylprednisolone can be tried on patients with partial response or with recent visual loss. Polymyalgia rheumatica in the absence of giant cell arteritis requires an initial dose of prednisone 10 to 20 mg/day. In some cases of mild polymyalgia rheumatica, a short course of nonsteroidal anti-inflammatory drugs may be tried. Long term corticosteroid therapy in polymyalgia rheumatica and giant cell arteritis is complicated by serious adverse effects in between 48 and 65% of patients. Vertebral fractures and infections are among the most dangerous and frequent complications. Although there are limited data on the use of cytotoxic or immunosuppressive drugs, such as methotrexate, azathioprine and cyclosporin, in these indications, they might be effective either in sparing corticosteroids or in treating patients who do not respond to treatment with corticosteroids.

Original languageEnglish
Pages (from-to)25-32
Number of pages8
JournalBioDrugs
Volume9
Issue number1
DOIs
Publication statusPublished - 1998

Fingerprint

Polymyalgia Rheumatica
Giant Cell Arteritis
Adrenal Cortex Hormones
Temporal Arteries
Blood Sedimentation
Prednisone
Pharmaceutical Preparations
Methylprednisolone
Azathioprine
Immunosuppressive Agents
Methotrexate
Cyclosporine
Physical Examination
Anti-Inflammatory Agents
Neck
Therapeutics
Biopsy
Pain
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Immunology and Allergy
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Diagnosis and management of polymyalgia rheumatica/giant cell arteritis. / Salvarani, Carlo; Macchioni, Luigi; Olivieri, Ignazio; Cantini, Fabrizio; Boiardi, Luigi.

In: BioDrugs, Vol. 9, No. 1, 1998, p. 25-32.

Research output: Contribution to journalArticle

Salvarani, Carlo ; Macchioni, Luigi ; Olivieri, Ignazio ; Cantini, Fabrizio ; Boiardi, Luigi. / Diagnosis and management of polymyalgia rheumatica/giant cell arteritis. In: BioDrugs. 1998 ; Vol. 9, No. 1. pp. 25-32.
@article{a58c2f6cdac44b8d852d1b202a3556d1,
title = "Diagnosis and management of polymyalgia rheumatica/giant cell arteritis",
abstract = "There are no standardised diagnostic criteria for polymyalgia rheumatica. The combination of persistent pain (at least 1 month) with marked morning stiffness in at least 2 of the neck, shoulder or pelvic girdle is characteristic of polymyalgia rheumatica. The other criteria are age >50 years, erythrocyte sedimentation rate (ESR) >40 mm/hour, rapid response to corticosteroids and an absence of other diseases capable of causing the musculoskeletal symptoms. A normal ESR does not exclude a diagnosis of polymyalgia rheumatica. Diagnostic temporal artery biopsy is recommended in all patients suspected of having giant cell arteritis. The segment of temporal artery with abnormality on physical examination should be biopsied. The drugs of choice in the treatment of polymyalgia rheumatica/giant cell arteritis are corticosteroids. An initial prednisone dosage of 40 to 60 mg/day is adequate in almost all cases of giant cell arteritis. Higher dosages and/or intravenous pulse methylprednisolone can be tried on patients with partial response or with recent visual loss. Polymyalgia rheumatica in the absence of giant cell arteritis requires an initial dose of prednisone 10 to 20 mg/day. In some cases of mild polymyalgia rheumatica, a short course of nonsteroidal anti-inflammatory drugs may be tried. Long term corticosteroid therapy in polymyalgia rheumatica and giant cell arteritis is complicated by serious adverse effects in between 48 and 65{\%} of patients. Vertebral fractures and infections are among the most dangerous and frequent complications. Although there are limited data on the use of cytotoxic or immunosuppressive drugs, such as methotrexate, azathioprine and cyclosporin, in these indications, they might be effective either in sparing corticosteroids or in treating patients who do not respond to treatment with corticosteroids.",
author = "Carlo Salvarani and Luigi Macchioni and Ignazio Olivieri and Fabrizio Cantini and Luigi Boiardi",
year = "1998",
doi = "10.2165/00063030-199809010-00003",
language = "English",
volume = "9",
pages = "25--32",
journal = "Clinical Immunotherapeutics",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Diagnosis and management of polymyalgia rheumatica/giant cell arteritis

AU - Salvarani, Carlo

AU - Macchioni, Luigi

AU - Olivieri, Ignazio

AU - Cantini, Fabrizio

AU - Boiardi, Luigi

PY - 1998

Y1 - 1998

N2 - There are no standardised diagnostic criteria for polymyalgia rheumatica. The combination of persistent pain (at least 1 month) with marked morning stiffness in at least 2 of the neck, shoulder or pelvic girdle is characteristic of polymyalgia rheumatica. The other criteria are age >50 years, erythrocyte sedimentation rate (ESR) >40 mm/hour, rapid response to corticosteroids and an absence of other diseases capable of causing the musculoskeletal symptoms. A normal ESR does not exclude a diagnosis of polymyalgia rheumatica. Diagnostic temporal artery biopsy is recommended in all patients suspected of having giant cell arteritis. The segment of temporal artery with abnormality on physical examination should be biopsied. The drugs of choice in the treatment of polymyalgia rheumatica/giant cell arteritis are corticosteroids. An initial prednisone dosage of 40 to 60 mg/day is adequate in almost all cases of giant cell arteritis. Higher dosages and/or intravenous pulse methylprednisolone can be tried on patients with partial response or with recent visual loss. Polymyalgia rheumatica in the absence of giant cell arteritis requires an initial dose of prednisone 10 to 20 mg/day. In some cases of mild polymyalgia rheumatica, a short course of nonsteroidal anti-inflammatory drugs may be tried. Long term corticosteroid therapy in polymyalgia rheumatica and giant cell arteritis is complicated by serious adverse effects in between 48 and 65% of patients. Vertebral fractures and infections are among the most dangerous and frequent complications. Although there are limited data on the use of cytotoxic or immunosuppressive drugs, such as methotrexate, azathioprine and cyclosporin, in these indications, they might be effective either in sparing corticosteroids or in treating patients who do not respond to treatment with corticosteroids.

AB - There are no standardised diagnostic criteria for polymyalgia rheumatica. The combination of persistent pain (at least 1 month) with marked morning stiffness in at least 2 of the neck, shoulder or pelvic girdle is characteristic of polymyalgia rheumatica. The other criteria are age >50 years, erythrocyte sedimentation rate (ESR) >40 mm/hour, rapid response to corticosteroids and an absence of other diseases capable of causing the musculoskeletal symptoms. A normal ESR does not exclude a diagnosis of polymyalgia rheumatica. Diagnostic temporal artery biopsy is recommended in all patients suspected of having giant cell arteritis. The segment of temporal artery with abnormality on physical examination should be biopsied. The drugs of choice in the treatment of polymyalgia rheumatica/giant cell arteritis are corticosteroids. An initial prednisone dosage of 40 to 60 mg/day is adequate in almost all cases of giant cell arteritis. Higher dosages and/or intravenous pulse methylprednisolone can be tried on patients with partial response or with recent visual loss. Polymyalgia rheumatica in the absence of giant cell arteritis requires an initial dose of prednisone 10 to 20 mg/day. In some cases of mild polymyalgia rheumatica, a short course of nonsteroidal anti-inflammatory drugs may be tried. Long term corticosteroid therapy in polymyalgia rheumatica and giant cell arteritis is complicated by serious adverse effects in between 48 and 65% of patients. Vertebral fractures and infections are among the most dangerous and frequent complications. Although there are limited data on the use of cytotoxic or immunosuppressive drugs, such as methotrexate, azathioprine and cyclosporin, in these indications, they might be effective either in sparing corticosteroids or in treating patients who do not respond to treatment with corticosteroids.

UR - http://www.scopus.com/inward/record.url?scp=0031983321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031983321&partnerID=8YFLogxK

U2 - 10.2165/00063030-199809010-00003

DO - 10.2165/00063030-199809010-00003

M3 - Article

C2 - 18020554

AN - SCOPUS:0031983321

VL - 9

SP - 25

EP - 32

JO - Clinical Immunotherapeutics

JF - Clinical Immunotherapeutics

SN - 1173-8804

IS - 1

ER -